Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Thyroid Neoplasms 3Thyroid Cancer, Papillary 1Parkinson Disease 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Immunoglobulin Light-chain Amyloidosis 1Adenocarcinoma, Follicular 1

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × Iodine-124 × Clear all
NCT05968846 2024-12-05

Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

University of Tennessee Graduate School of Medicine

Phase 2 Completed
19 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡